Meeting
2019 ASCO Annual Meeting
Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.
Authors
Yvonne Brandberg
Karolinska Institutet, Department of Oncology-Pathology (OnkPat), Karolinska University Hospital, Stockholm, Sweden
Yvonne Brandberg , Anne Andersson , Judith Bjohle , Ana Bosch , Lena Carlsson , Ann Charlotte Dreifaldt , Zakaria Einbeigi , Hanna Fredholm , Erika Isaksson-Friman , Theodoros Foukakis , Ellinor Elinder , Mats Hellstrom , Hemming Johansson , Tobias Lekberg , Henrik Lindman , Jonas C. S. Bergh , Thomas Hatschek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT02568839
Citation
J Clin Oncol 37, 2019 (suppl; abstr 583)
DOI
10.1200/JCO.2019.37.15_suppl.583
Abstract #
583
Poster Bd #
75
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.
First Author: Yvonne Brandberg
Poster
2022 ASCO Annual Meeting
Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.
First Author: Alexios Matikas
Poster
2014 ASCO Annual Meeting
Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer.
First Author: Joseph B. Babigumira
Poster
2023 ASCO Breakthrough
Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.
First Author: WanChen Hsieh